

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

**ESTABLISHMENT OF THE ENVIRONMENTAL, SOCIAL AND
GOVERNANCE COMMITTEE
AND
APPOINTMENT OF COMMITTEE MEMBERS**

The board of directors (the “**Directors**”) of the Company (the “**Board**”) of WuXi Biologics (Cayman) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that an environmental, social and governance committee of the Board (the “**ESG Committee**”) was established on March 23, 2021.

The ESG Committee is mainly responsible for (i) guiding and formulating the Group’s environmental, social and governance (“**ESG**”) vision, objectives, strategies and structure to ensure that they are in line with the needs of the Group and comply with applicable laws, regulations, regulatory requirements and international standards; (ii) monitoring the development and implementation of the Group’s ESG vision, strategies and structure; (iii) guiding and reviewing the identification and ranking of important ESG issues of the Group; (iv) reviewing the key ESG trends and related risks and opportunities, and assessing the adequacy and effectiveness of the Group’s ESG structure accordingly; (v) monitoring the channels and means of communication with the Group’s stakeholders and ensuring that the relevant policies are in place to effectively promote the relationship between the Group and its stakeholders and protect the Group’s reputation; and (vi) reviewing the Company’s ESG report and other ESG related disclosures, and making recommendations to the Board, so as to promote the continuous improvement of the ESG performance of the Group.

The members of the ESG Committee are Dr. Zhisheng Chen, Mr. Kenneth Walton Hitchner III and Mr. William Robert Keller, and Dr. Zhisheng Chen has been appointed as the chairman of the ESG Committee. The terms of reference of the ESG Committee will be posted on the website of the Company.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, March 23, 2021

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Edward Hu, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Kenneth Walton Hitchner III as independent non-executive Directors.

* *For identification purpose only*